Mutations of the BRAF gene in human cancer, Nature. juin, vol.417, issue.6892, pp.949-54, 2002. ,
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer, J Clin Oncol Off J Am Soc Clin Oncol. 10 août, vol.35, issue.23, pp.2624-2654, 2017. ,
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, vol.117, issue.20, pp.4623-4655, 2011. ,
Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation, Int J Cancer. 1 mai, vol.128, issue.9, pp.2075-84, 2011. ,
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status, Mol Cancer. 10 janv, vol.5, issue.2, 2006. ,
BRAF Mutation in Metastatic Colorectal Cancer, N Engl J Med. 2 juill, vol.361, issue.1, pp.98-107, 2009. ,
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, Br J Cancer. août, vol.101, issue.3, pp.465-72, 2009. ,
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer, N Engl J Med, vol.371, issue.17, pp.1609-1627, 2014. ,
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer, Eur J Cancer. janv, vol.50, issue.1, pp.57-63, 2014. ,
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer, Nucleic Acids Res. janv, vol.38, issue.suppl_1, pp.652-659, 2010. ,
Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool, Am J Clin Pathol, vol.144, issue.4, pp.620-628, 2015. ,
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by nextgeneration sequencing: findings from the CAPRI-GOIM trial, Ann Oncol. sept, vol.25, issue.9, pp.1756-61, 2014. ,
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis, Ann Oncol Off J Eur Soc Med Oncol, vol.26, issue.10, pp.2092-2099, 2015. ,
Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis, Oncology, vol.91, issue.3, pp.162-70, 2016. ,
BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer, Clin Cancer Res. 1 juin, vol.23, issue.11, pp.2742-2751, 2017. ,
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors, Cancer Res. 1 déc, vol.63, issue.23, pp.8132-8139, 2003. ,
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell. 19 mars, vol.116, issue.6, pp.855-67, 2004. ,
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS, Nature, vol.10, issue.7666, pp.234-242, 2017. ,
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study, Br J Cancer, vol.117, issue.10, pp.1450-1458, 2017. ,
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF, BMC Cancer, vol.15, p.779, 2015. ,
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience, Oncotarget. 27 juin, vol.8, issue.26, pp.42198-213, 2017. ,
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, Lancet Oncol, vol.16, issue.13, pp.1306-1321, 2015. ,
Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor: Outcome and adjuvant chemotherapy in signet-ring cell carcinoma, Int J Cancer. 15 janv, vol.136, issue.2, pp.333-342, 2015. ,
Pattern of distant metastases in colorectal cancer: a SEER based study, Oncotarget, issue.17, 2015. ,
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial, JAMA. 20 juin, vol.317, issue.23, p.2392, 2017. ,
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database, Lancet Oncol. déc, vol.17, issue.12, pp.1709-1728, 2016. ,
Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin, vol.5, 2016. ,
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study, Ann Oncol. 1 mai, vol.29, issue.5, pp.1211-1220, 2018. ,
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies, Clin Cancer Res, vol.20, issue.20, pp.5322-5352, 2014. ,
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer. janv, vol.100, issue.2, pp.266-73, 2009. ,
BRAF Mutants Evade ERKDependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition, Cancer Cell. sept, vol.28, issue.3, pp.370-83, 2015. ,
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, openlabel, Lancet Oncol. sept, vol.15, issue.10, pp.1065-75, 2014. ,
What is the prognostic impact of BRAF mutation in patients undergoing resection of colorectal liver metastases? Results of nationwide intergroup (ACHBT, FRENCH, AGEO) cohort of 249 patients, J Clin Oncol. 20 mai, vol.36, issue.15_suppl, pp.3554-3554, 2018. ,
pronostic et chimiosensibilité des mutations BRAF non V600E des adénocarcinomes colorectaux métastatiques RESUME Introduction : Les adénocarcinomes colorectaux métastatiques (CCRm) avec mutation BRAF non V600E sont rares (2,2%) ,
Il s'agissait d'une cohorte multicentrique rétrospective française incluant les CCRm mutés BRAF non V600E, divisés en 3 groupes : prise en charge curative des métastases (groupe 1, n=35), chimiothérapie palliative (groupe 2, n=63) ,
, Leur localisation ainsi que leur dissémination métastatique étaient classiques. Il y avait surtout des adénocarcinomes bien et moyennement différenciés (88%). Les mutations BRAF les plus fréquentes, Résultats : Les 108 patients inclus avaient un âge médian au diagnostic métastatique de 66 ans, vol.21
, La chimiosensibilité était bonne avec 49,0% de réponse objective et 76,8% de taux de contrôle en 1 ère ligne dans les groupes 1 et 2. Les taux de réponse étaient semblables entre les antiEGFr et les antiVEGF. La médiane de survie globale (mSG), vol.105, p.1
, 16 mois et 8 mois. Il n'existait pas de différence de mSG en fonction du type de mutation (notamment pour D594 et K601) ni de l'impact fonctionnel sur BRAF
, Conclusion : Les CCRm mutés BRAF non V600E sont de bon pronostic, avec une bonne chimiosensibilité
, Mots clés : cancer colorectal, métastatique, mutation BRAF non V600E, pronostic, chimiosensibilité Epidemiology, prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal adenocarcinoma